載入中
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
最新資料
US$0.6733
−US$0.0479 · -6.64%
盤中時間採用ET。市場資料可能有所延遲。
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
97
深度低估
情緒
46
多空交錯
風險
66
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5342.6萬 USD | 2538.4萬 USD | — | — | — |
| 銷貨成本 | 374.7萬 USD | 161.8萬 USD | — | — | — |
| 毛利 | 4967.9萬 USD | 2376.6萬 USD | — | — | — |
| 研究與開發 | 3830.8萬 USD | 1.37億 USD | 1.59億 USD | 1.79億 USD | 1.83億 USD |
| 銷售、一般及管理費用 | 6693.1萬 USD | 6338.8萬 USD | 4912.5萬 USD | 4704.4萬 USD | 3651.7萬 USD |
| 營業費用 | 1.05億 USD | 2.01億 USD | 2.13億 USD | 2.48億 USD | 2.27億 USD |
| 利息收入 | — | 695.1萬 USD | — | 671.4萬 USD | — |
| 利息支出 | — | — | — | 4308.4萬 USD | — |
| 折舊和攤銷 | 210.7萬 USD | 311.3萬 USD | 202.8萬 USD | 46.2萬 USD | 1000 USD |
| 營業利益 | −5556萬 USD | −1.77億 USD | −2.13億 USD | −2.48億 USD | −2.27億 USD |
| 淨利 | −5248.9萬 USD | −1.7億 USD | −1.99億 USD | −2.41億 USD | −2.27億 USD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$9.50
上漲空間 1310.96%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI743.44萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM415.98萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF245.67萬0.00%954億 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO115.61萬0.01%180億 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC49.5萬0.04%13.17億 USD0.60%US$181.66-0.73%
iShares Core S&P Total U.S. Stock Market ETFITOT42.64萬0.00%980.88億 USD0.03%US$169.43-0.14%
Virtus Biotech Clinical Trials ETFBBC29.72萬0.71%4191.31萬 USD0.65%US$43.13-2.30%
Vanguard Russell 2000 Value ETFVTWV18.61萬0.01%14億 USD0.06%US$185.97+0.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTVirtus Biotech Clinical Trials ETFBBCVanguard Russell 2000 Value ETFVTWVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
